e-learning resources

Efficacy of once-daily (o.d.) indacaterol/glycopyrronium/mometasone (IND/GLY/MF) vs free combination of twice-daily salmeterol/fluticasone (SAL/FLU) & o.d. tiotropium with respect to age, age at asthma-onset & BMI at baseline: ARGON subgroup analysis

R. Van Zyl-Smit (Cape Town, South Africa), D. Lawrence (Basel, Switzerland), K. Mezzi (Basel, Switzerland), D. Brittain (Basel, Switzerland), X. Jaumont (Basel, Switzerland), C. Gessner (Leipzig, Germany)

Source: International Congress 2022 – Clinical treatment of asthma
Session: Clinical treatment of asthma
 Session type: Thematic Poster
 Number: 3859

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Van Zyl-Smit (Cape Town, South Africa), D. Lawrence (Basel, Switzerland), K. Mezzi (Basel, Switzerland), D. Brittain (Basel, Switzerland), X. Jaumont (Basel, Switzerland), C. Gessner (Leipzig, Germany). Efficacy of once-daily (o.d.) indacaterol/glycopyrronium/mometasone (IND/GLY/MF) vs free combination of twice-daily salmeterol/fluticasone (SAL/FLU) & o.d. tiotropium with respect to age, age at asthma-onset & BMI at baseline: ARGON subgroup analysis. 3859

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.